|
Characteristics
|
Miliary TB (19) N (%)
|
Non-miliary TB (26) N (%)
|
Total (45) N (%)
|
Crude Orb (95% CI)
|
P value
|
|---|
|
Gender
|
|
Male
|
18 (94.7)
|
24 (92.3)
|
42 (93.3)
|
1
|
Ref.
|
|
Female
|
1 (5.3)
|
2 (7.7)
|
3 (6.7)
|
0.667 (0.056–7.937)
|
0.748
|
|
Age group (years)
|
|
< 25
|
7 (36.8)
|
2 (7.7)
|
9 (20.0)
|
8.167 (1.412–47.221)
|
0.019
|
|
25–44
|
9 (47.4)
|
21 (80.8)
|
30 (66.7)
|
1
|
Ref.
|
|
45–64
|
3 (15.8)
|
2 (7.7)
|
5 (11.1)
|
3.500 (0.497–24.654)
|
0.208
|
|
> 64
|
0 (0.0)
|
1 (3.8)
|
1 (2.2)
|
–
|
1
|
|
Initial CD4 cell count
|
|
> 100
|
1 (5.3)
|
1 (3.8)
|
2 (4.4)
|
1
|
Ref.
|
|
50–100
|
1 (5.3)
|
2 (7.7)
|
3 (6.7)
|
0.500 (0.013–19.562)
|
0.711
|
|
< 50
|
17 (89.5)
|
23 (88.5)
|
40 (88.9)
|
0.739 (0.043–12.674)
|
0.835
|
|
CD4 cell count after ART
|
|
> 100
|
6 (31.6)
|
15 (57.7)
|
21 (46.7)
|
1
|
Ref.
|
|
50–100
|
8 (42.1)
|
8 (30.8)
|
16 (35.5)
|
2.500 (0.640–9.766)
|
0.188
|
|
< 50
|
5 (26.3)
|
3 (11.5)
|
8 (17.8)
|
4.167 (0.749–23.179)
|
0.103
|
|
Increase in CD4 cell count
|
|
< 4 folds
|
9 (47.4)
|
12 (46.2)
|
21 (46.7)
|
1
|
Ref.
|
|
≥ 4 folds
|
10 (52.6)
|
14 (53.8)
|
24 (53.3)
|
0.952 (0.291–3.117)
|
0.936
|
|
HIV virial load
|
|
≤ 1000 copies
|
10 (52.6)
|
14 (53.8)
|
24 (53.3)
|
1
|
Ref.
|
|
> 1000 copies
|
9 (47.4)
|
12 (46.2)
|
21 (46.7)
|
1.050 (0.321–3.436)
|
0.936
|
|
HAART regimena
|
|
First-line
|
15 (78.9)
|
23 (88.5)
|
38 (84.4)
|
1
|
Ref.
|
|
Second-line
|
4 (21.1)
|
3 (11.5)
|
7 (15.6)
|
2.044 (0.400–10.457)
|
0.390
|
- aFirst-line regimen includes tenofovir, lamivudine and efavirenz; Second-line regimen includes tenofovir, lamivudine and lopinavir/ritonavir
- bOR, odds ratio; CI, confidential interval
